Biosimilars differentiated by innovative injection technology
FINOX Biotech develops biosimilars and combines them with specifically designed injection technologies
Thereby we positively differentiate our combination-products compared to the reference products
With our biosimilars, we want to create value for patients, partners and our investors:
Thereby we positively differentiate our combination-products compared to the reference products
With our biosimilars, we want to create value for patients, partners and our investors:
- for patients - with safe, efficient, easy to administer and fairly priced treatment of the highest quality
- for partners and investors - based on reciprocity, transparent business
Partnerships We are currently looking for strategic and/or financial partnerships for our first product, that support our market entry in Europe and late stage clinical development in the USA - contact us!
FINOX Biotech was founded 2007 in Switzerland and has since been working on implementing its vision
